Pelage Pharmaceutical raised $14M in a Series A-1 funding led by GV to accelerate its Phase 2 clinical program for hair loss treatments.

Aug 13, 2024•over 1 year ago

Amount Raised

$14 Million

Los AngelesBiotechnologyHealthcare

Investors

Description

Pelage Pharmaceutical, a clinical-stage regenerative medicine company, raised $14M in Series A-1 funding. The funds will be used to speed up its Phase 2 clinical program for treating hair loss, specifically targeting androgenetic alopecia and chemotherapy-induced alopecia.

Company Information

Company

Pelage Pharmaceuticals

Location

Los Angeles, California, United States

About

Pelage Pharmaceuticals is a clinical-stage regenerative medicine company developing first-in-class treatments for hair loss. With a focus on stem cell biology and metabolism, Pelage is advancing a new class of treatments designed to reactivate dormant hair follicle stem cells and restore the body’s ability to naturally grow hair. Its lead program, PP405, is currently in Phase 2a clinical trials. Through its rigorous scientific foundation, Pelage is pioneering first-in-class hair growth solutions for people of all hair types experiencing hair loss.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends